Clinical trials: immunohistochemistry staining method, completed
Lung Cancer
Biomarkers Predicting Response in Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride
RATIONALE: Studying samples of blood in the laboratory from patients receiving erlotinib hydrochloride may help doctors learn more about the effects of erlotinib hydrochloride on cells.
- Trial name
- NCT01123460
- Testing
- enzyme-linked immunosorbent assay, laboratory biomarker analysis
- Volunteers
- 127 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma (Skin)
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
RATIONALE: Interleukin-21 may stimulate white blood cells, including natural killer cells, to kill melanoma cells. PURPOSE: This phase II trial is studying the side effects and how well interleukin-21 works in treating patients…
- Trial name
- NCT00514085
- Testing
- recombinant human interleukin-21, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 7 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Adult Primary Liver Cancer, Hepatitis C Infection
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
This randomized phase II trial studies how well S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) works compared to a placebo in preventing liver cancer in patients with chronic hepatitis C infection.
- Trial name
- NCT00513461
- Testing
- S-adenosyl-L-methionine disulfate p-toluene-sulfonate, laboratory biomarker analysis, immunoenzyme technique
- Where
- 5 sites in United States
- Volunteers
- 110 people
- Sponsor
- Chao Family Comprehensive Cancer Center
Breast Cancer
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is most effective in treating breast cancer.
- Trial name
- NCT00640861
- Testing
- CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Unspecified Adult Solid Tumor, Protocol Specific
Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00389922
- Testing
- lapatinib ditosylate, vinorelbine ditartrate, comparative genomic hybridization
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of California, Davis
Colon Cancer, Rectal Cancer
Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
45 patients undergoing a colon (large bowel/intestine)removal operation for the diagnosis of colon cancer will be included in this study. During colon operation the affected portion of the colon is removed.
- Trial name
- NCT01902953
- Testing
- Lymphoseek and VBD Sln dissection
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Maimonides Medical Center
Surgical Retinal
CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases
The aims of this study were to analyze CD160 expression in both normal and pathological eyes from human adults to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease
- Trial name
- NEOVASC-CD160 (NCT03940664)
- Testing
- immunohistochemistry on Formalin fixed and paraffin embedded blocks
- Where
- France
- Volunteers
- 75 people
- Sponsor
- CHU de Reims
Thyroid Cancer
Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer
This multi-center study aims at NTRK fusion testing of all patients with advanced thyroid cancer (any histotype and regardless of stage).
- Trial name
- NTRK (NCT05796258)
- Testing
- NTRK fusion assessment
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Regina Elena Cancer Institute
Non Small-cell Lung Cancer
Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)
Because ALK-positive lung cancer constitutes less than 5% of all lung cancers, it is critically important to select those patients who are more likely to have the ALK mutation.
- Trial name
- ALK (NCT01662635)
- Where
- Mexico
- Volunteers
- 230 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Diabetes Mellitus Arising in Pregnancy, Insulin-Requiring, Diabetes Mellitus in Pregnancy
Comparative Effects of Metformin and Insulin on Stereological Studies and Immunohistochemistry of Placenta
Diabetes mellitus is a group of metabolic disorder characterized by high blood glucose level mainly due to defect in insulin secretion or resistance.
- Trial name
- NCT04907708
- Testing
- Metformin, Insulin
- Where
- Pakistan
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- University of Karachi
Head and Neck Cancer
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00720304
- Testing
- docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Comprehensive Cancer Center
Kidney Cancer
Studying Biomarkers in Samples From Younger Patients With Wilms Tumor
RATIONALE: Studying samples of tissue and urine from patients with cancer in the laboratory may help doctor learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01542333
- Testing
- gene expression analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Mitochondrial Diseases, Developmental Delay Disorder
Reference Values of Intraepidermal Nerve Fiber Density in Children and Small Fiber Neuropathy in Neurodevelopmental Disorders
Background: Small-Fiber-Neuropathy describes the degeneration of mildly or unmyelinated nerve fibers and causes neuropathic pain and autonomic dysfunction.
- Conditions
- Mitochondrial Diseases, Developmental Delay Disorder, Small Fiber Neuropathy, Cerebral Palsy
- Trial name
- SFN_children (NCT05645874)
- Testing
- Skin biopsy
- Where
- Germany
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Breast Cancer
Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899418
- Testing
- gene expression analysis, polymerase chain reaction, polymorphism analysis
- Volunteers
- 500 people
- Sponsor
- Eastern Cooperative Oncology Group
Neuroblastoma
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01387724
- Testing
- RNA analysis, polymerase chain reaction, protein expression analysis
- Volunteers
- 300 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898664
- Testing
- cytogenetic analysis, gene expression analysis, mutation analysis
- Volunteers
- 74 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non-Small Cell Lung Cancer
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This is a Phase 2, multicenter study designed to evaluate the efficacy and safety of trastuzumab emtansine administered as a single-agent in participants with HER2-positive (HER2 IHC 2+ or HER2 IHC 3+) advanced or metastatic…
- Trial name
- NCT02289833
- Testing
- Trastuzumab Emtansine
- Where
- 23 sites in United States, Germany and 5 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00810797
- Testing
- exemestane, laboratory biomarker analysis, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Endometriosis Outside Pelvis
Assessment of Surgically Removed Abdominal Wall Endometriomas
A retrospective review of all patients who underwent surgery for an anterior abdominal wall mass which confirmed by pathology examination as an endometrioma will be completely performed.
- Trial name
- NCT04639063
- Testing
- Microscopic examination using H&E stained slides
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Al-Azhar University
Neoplasm Malignant
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
This is a multi-center, open-label, monotherapy dose escalation, PK bridging, and dose expansion Phase I/IIa study in Chinese adult subjects to evaluate the safety, tolerability, Pharmacokinetics (PK) profiles, immunogenicity…
- Trial name
- NCT06238687
- Testing
- STRO-002
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd